đź“‹ Regulatory Action / Label Change
Cala Health announced nationwide availability of the Cala kIQ Plus System on October 6, 2026, following FDA clearance earlier that year. The prescription wearable delivers transcutaneous afferent patterned stimulation (TAPS) for temporary hand tremor relief in adults with essential tremor and Parkinson’s disease. The system includes three selectable stimulation waveforms and adaptive calibration before each session. The article describes these features alongside company-reported conference findings on tremor severity and daily functioning.
Professional Impact
- Essential tremor: The indication covers temporary relief of hand tremor in the treated hand following stimulation.
- Parkinson’s disease: The indication covers temporary relief of postural and kinetic hand tremor affecting certain daily activities.
- Users can switch among three stimulation modes, with calibration before each session to account for changes in tremor characteristics.
- According to the company, preferred-waveform treatment produced greater improvement on the Bain and Findley Activities of Daily Living scale than traditional-waveform treatment.
- Across stimulation modes, 76%–89% of patients achieved at least a one-point reduction on the clinician-rated tremor performance score reported in the article.
Action Items
- Initiate treatment with the fully assembled system and its on-device guidance, as described in the article.
- Select or change stimulation modes according to user preference; the system calibrates before each therapy session.
- Repeat therapy throughout the day, an operating feature reported by the publisher.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS